Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice.
de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, Seals DR. · 2016
Read Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. by de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, Seals DR. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4854911.txt.
Introduction
Natalie E. de Picciotto and co-authors tested in 2016 whether a nutrient called NMN could undo age-linked blood vessel decline in mice. NMN feeds production of NAD+, a cell helper that falls with age. Old mice showed stiff arteries and poor vessel widening next to young mice, tied to oxidative stress and low activity of a vessel enzyme, SIRT1.
NMN in drinking water restored vessel widening and eased stiffness in old mice. Oxidative stress markers fell and the protective enzyme's activity rose. Young mice gained little, since their vessels were already sound. The results point to NAD+ support as a route to protect aging arteries, at least in animals.
Catalog record
| CREATOR | de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, Seals DR. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice By Natalie E. de Picciotto, Lindsey B. Gano, Lawrence C. Johnson, Christopher R. Martens, Amy L. Sindler, Kathryn F. Mills, Shin‐ichiro Imai, Douglas R. Seals Published in: Aging Cell DOI: 10.1111/acel.12461 ABSTRACT Summary We tested the hypothesis that supplementation of nicotinamide mononucleotide (NMN), a key NAD + intermediate, increases arterial SIRT1 activity and reverses age‐associated arterial dysfunction and oxidative stress. Old control mice (OC) had impaired carotid artery endothelium‐dependent dilation (EDD) (60 ± 5% vs. 84 ± 2%), a measure of endothelial function, and nitric oxide (NO)‐mediated EDD (37 ± 4% vs. 66 ± 6%), compared with young mice (YC). This age‐associated impairment in EDD was restored in OC by the superoxide (O2−) scavenger TEMPOL (82 ± 7%). OC also had increased aortic pulse wave velocity (aPWV, 464 ± 31 cm s−1 vs. 337 ± 3 cm s−1) and elastic modulus (EM, 6407 ± 876 kPa vs. 3119 ± 471 kPa), measures of large elastic artery stiffness, compared with YC. OC had greater aortic O2− production (2.0 ± 0.1 vs. 1.0 ± 0.1 AU), nitrotyrosine abundance (a marker of oxidative stress), and collagen‐I, and reduced elastin and vascular SIRT1 activity, measured by the acetylation status of the p65 subunit of NFκB, compared with YC. Supplementation with NMN in old mice restored EDD (86 ± 2%) and NO‐mediated EDD (61 ± 5%), reduced aPWV (359 ± 14 cm s−1) and EM (3694 ± 315 kPa), normalized O2− production (0.9 ± 0.1 AU), decreased nitrotyrosine, reversed collagen‐I, increased elastin, and restored vascular SIRT1 activity. Acute NMN incubation in isolated aortas increased NAD + threefold and manganese superoxide dismutase (MnSOD) by 50%. NMN supplementation may represent a novel therapy to restore SIRT1 activity and reverse age‐related arterial dysfunction by decreasing oxidative stress. INTRODUCTION Cardiovascular diseases (CVD) remain the leading cause of morbidity and mortality in developed nations (Mortality & Causes of Death, 2014), and advancing age is the primary risk factor for CVD (Lakatta & Levy, 2003). The number of older adults in the developed world is expected to at least double by 2050 (Petsko, 2008), and this is associated with projections of marked increases in CVD burden (Heidenreich et al., 2011). Therefore, there is an urgent need to develop treatments that reduce the risk of CVD with aging. Two key antecedents and independent predictors of clinical CVD in older adults are vascular endothelial dysfunction, assessed by endothelium‐dependent dilation (EDD), and large elastic artery stiffness, measured by aortic pulse wave velocity (aPWV) (Lakatta & Levy, 2003; Deanfield et al., 2007; Yeboah et al., 2007; Mitchell et al., 2010). A common mechanism that contributes to both vascular endothelial dysfunction and large elastic artery stiffness with aging is excessive superoxide‐associated vascular oxidative stress (Seals et al., 2011; Fleenor et al., 2012a; Bachschmid et al., 2013). Increased vascular production of superoxide occurs with aging and reduces the bioavailability of the vasoprotective and vasodilatory molecule nitric oxide (NO), while also causing alterations in major structural proteins (collagen and elastin) in the large elastic arteries (i.e., the aorta and carotid arteries) (Deanfield et al., 2007; Fleenor et al., 2010; Seals et al., 2014). These changes contribute directly to age‐related endothelial dysfunction and increased arterial stiffness (Lakatta & Levy, 2003; Seals et al., 2011). As such, treatments that reduce the excessive superoxide production in aging arteries hold the potential for improving age‐associated vascular dysfunction. We have previously shown that lifelong caloric restriction (CR), as well as short‐term CR in old animals, prevents or reverses endothelial dysfunction and large elastic artery stiffening by reducing superoxide production, increasing NO bioavailability, and modifying structural proteins (Rippe et al., 2010; Donato et al., 2013). However, because adherence to CR is not practical for most humans, there is growing interest in pharmacological therapies that may induce the benefits of CR. In this context, the mammalian SIRT1, one of seven members in the sirtuin family of protein deacetylases/deacylases, is a nicotinamide adenine dinucleotide (NAD+)‐dependent deacetylase that acts as a metabolic energy sensor implicated in several of the beneficial effects of CR, including reduced oxidative stress (Boily et al., 2008; Merksamer et al., 2013). Our previous work shows that reduced SIRT1 expression and activity is a key mechanism mediating impaired EDD in aging arteries (Rippe et al., 2010; Donato et al., 2011; Gano et al., 2014), and our recent findings indicate that pharmacological activation of SIRT1 with the compound SRT1720 improves EDD in old mice in part by reducing oxidative stress (Gano et al., 2014). Supplementation with nicotinamide mononucleotide (NMN), a key NAD+ intermediate, activates SIRT1 and improves metabolic and stress responses with aging in mice (Yoshino et al., 2011; Gomes et al., 2013). Thus, NMN is viewed as a promising therapy for age‐associated physiological dysfunction and disease (Imai, 2010; Yoshino et al., 2011). However, it is unknown whether NMN supplementation can increase arterial SIRT1 activity, reduce vascular oxidative stress, and reverse vascular dysfunction with aging. In the present study, we tested this hypothesis, while also assessing the effects of NMN on vascular superoxide production, NO bioavailability, and collagen and elastin expression. Acetylation status of the p65 subunit of nuclear factor kappa B (NFκB), a well‐established target of SIRT1, was used to determine activation of the enzyme, as described previously (Yoshino et al., 2011; Gano et al., 2014). RESULTS Animal characteristics and NMN intake Selected morphological characteristics are shown in Table 1. There were no differences in body mass across the four groups. We observed an age‐related increase in heart mass and a decrease in fat and muscle mass, which were not altered with NMN treatment. All animals consumed the same quantity of food throughout the duration of the study, and average NMN intake was similar in both young and old treated groups (data not shown). [Table: Animal Characteristics] NMN treatment restores maximum EDD and NO‐mediated EDD in old mice Baseline carotid artery diameters (μm) assessed ex vivo were greater in old mice (controls: 480 ± 17; treated: 478 ± 9) vs. young mice (controls: 424 ± 4; treated: 432 ± 5), as we have previously reported (Sindler et al., 2011). NMN supplementation had no effect on baseline carotid artery diameters. Maximum EDD to acetylcholine assessed ex vivo was lower in old control compared with young control mice and was mediated in part by a diminished NO dilatory influence, as indicated by a smaller reduction in EDD in the presence vs. absence of the NO synthase inhibitor N‐G‐nitro‐L‐arginine‐methyl ester (l‐NAME) (Fig. 1A,B). NMN supplementation rescued EDD in old mice by restoring NO‐mediated dilation, but had no effect in young treated animals (Fig. 1A,B). There were no differences in maximal EDD or NO‐mediated EDD in young and old treated animals vs. young controls (Fig. 1 A,B). Endothelium‐independent dilation to the NO donor sodium nitroprusside, a control to assess vascular smooth muscle sensitivity to NO, was not different among the groups (Fig. 1C). [Figure: Endothelium‐dependent, nitric oxide (NO)‐dependent, and endothelium‐independent dilation. (A) Dose–responses to the endothelium‐dependent dilator acetylcholine (ACh) in young and old control (YC and OC) and young and old NMN‐supplemented (YNMN and ONMN) mice (n = 13–22 per group). (B) NO‐dependent dilation (Max DilationACh − Max DilationACh + l‐NAME) (n = 5–12 per